Rotate between 4 quadrants each week: right upper, left upper, left lower, right lower
Popular GLP-1 medications are priced around $99 a month in many developed nations, but at $499 a month to cash-pay patients in the United States
FDA approval, if granted, is not expected before 2027
The Three Generations of Incretin Peptide Research The progression from single to dual to triple agonist peptides represents a research trajectory that has played out in roughly ten years: Generation 1 Single GLP-1 Agonists (Semaglutide, Liraglutide, Exenatide) The first incretin peptides to reach broad clinical research were GLP-1 receptor agonists
Best for: self-pay patients who want the broadest medication menu at the lowest entry price and are disciplined enough to read the FAQ before subscribing
The question is not whether these medications work